Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
10.4111/kju.2015.56.7.498
- Author:
Ju Hyun LIM
1
;
In Gab JEONG
;
Jong Yeon PARK
;
Dalsan YOU
;
Bumsik HONG
;
Jun Hyuk HONG
;
Hanjong AHN
;
Choung Soo KIM
Author Information
1. Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
- Publication Type:Original Article
- Keywords:
Carcinoma;
Hydroxymethylglutaryl-CoA reductase inhibitors;
Transitional cell carcinoma
- MeSH:
Aged;
Carcinoma, Transitional Cell/pathology/*surgery;
Female;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use;
Kidney Neoplasms/pathology/*surgery;
Male;
Middle Aged;
Neoplasm Grading;
Neoplasm Staging;
Nephrectomy/methods;
Preoperative Care/methods;
Prognosis;
Recurrence;
Retrospective Studies;
Survival Analysis;
Ureteral Neoplasms/pathology/*surgery
- From:Korean Journal of Urology
2015;56(7):498-504
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The objective was to investigate the impact of statin use on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: A retrospective review of medical records identified 277 patients who underwent radical nephroureterectomy for primary UTUC at Asan Medical Center between January 2006 and December 2011. Information on preoperative statin use was obtained from patient charts in an electronic database. We assessed the impact of statin use on recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). RESULTS: Of these 277 patients, 62 (22.4%) were taking statin medications. Compared to the statin nonusers, the statin users were older, had a higher body mass index, and had higher rates of cardiovascular disease and diabetes. The 5-year RFS rates of statin users and nonusers were 78.5% and 72.5%, respectively (p=0.528); the 5-year CSS rates were 85.6% and 77.7%, respectively (p=0.516); and the 5-year OS rates were 74.5% and 71.4%, respectively (p=0.945). In the multivariate analysis, statin use was not an independent prognostic factor for RFS (hazard ratio, 0.47; p=0.056), CSS (hazard ratio, 0.46; p=0.093), or OS (hazard ratio, 0.59; p=0.144) in patients who underwent radical nephroureterectomy for UTUC. CONCLUSIONS: Statin use was not associated with improved RFS, CSS, or OS in the sample population of patients with UTUC.
